Final Results of the KING trial: Phase 2 Study of Efficacy, Safety and Intratumoral Pharmacokinetics of Selinexor (KPT-330) Monotherapy in Recurrent Glioblastoma

Andrew B. Lassman¹, Patrick Y. Wen², Martin van den Bent³, Scott R. Plotkin⁴, Annemiek Walenkamp⁵, Adam Green⁶, Hongwei Wang⁷, Kai Li⁷, Yang Liu⁷, Hongmei Xu⁷, Jatin Shah⁷, Michael G. Kauffman⁷, Sharon Shacham⁷, Morten Mau-Soerensen⁸

¹Columbia University Irving Medical Center, New York, NY, USA; ²Dana Farber Cancer Institute, Boston, MA, USA; ³Erasmus MC Cancer Center, Rotterdam, The Netherlands; ⁴Massachusetts General Hospital, Boston, MA, USA; ⁵University of Groningen, Groningen, The Netherlands; ⁶Currently: University of Colorado, School of Medicine, Aurora, CO; ⁷Karyopharm Therapeutics Inc, Newton MA, USA; ⁸Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Presented at 2020 Society for Neuro-Oncology Annual Meeting Virtually
Disclosure

Last 12 months, commercial organization that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients

- **Honoraria, Consulting, Advisory Board**: Abbott Molecular, AbbVie, Bayer, Bioclinica as an expert blinded independent reviewer for a BMS-sponsored trial, Forma, Karyopharm, Novocure, Orbus, QED, Sapience

- **Speakers’ Bureau, Executive Positions**: None

- **Stock**: None

- **Funding** and drug supply for this clinical trial from Karopharm

Will discuss off-label use of selinexor for glioblastoma
Selinexor: First-in-Class, Oral Selective Inhibitor of Nuclear Export (SINE) Drug

Exportin 1 (XPO1) is the major nuclear export protein of:
1. Tumor suppressor proteins (TSPs, e.g. p53, pRb, IĸB, p27, p21, FOXOs)
2. eIF4E-bound proto-oncogene mRNAs (e.g. c-Myc, Bcl2, Bcl6, BclXL)

Elevated XPO1 expression:
1. Inactivates TSP’s by mislocalization
2. Enhances proto-oncoprotein translation

Selinexor is an oral selective inhibitor of XPO1 that:
1. Reactivates TSP’s and blocks proto-oncoprotein translation
2. Blocks DNA damage repair
3. Decreases gene translation efficacy in glioblastoma
4. Induces glioblastoma death
5. Synergies with temozolomide and radiation

Green et al., Neuro-Oncology, 2015; Argueta et al., Oncotarget, 2018; Shang et al., Sci Rep, 2018; Wahba et al., MCT, 2018

Presented By: Andrew B. Lassman, MS, MD
Selinexor: First-in-Class, Oral Selective Inhibitor of Nuclear Export (SINE) Drug

Exportin 1 (XPO1) is the major nuclear export protein of:
1. Tumor suppressor proteins (TSPs, e.g. p53, pRb, IkB, p27, p21, FOXOs)
2. eIF4E-bound proto-oncogene mRNAs (e.g. c-Myc, Bcl2, Bcl6, BclXL)

Elevated XPO1 expression:
1. Inactivates TSP’s by mislocalization
2. Enhances proto-oncoprotein translation

Selinexor is an oral selective inhibitor of XPO1 that:
1. Reactivates TSP’s and blocks proto-oncoprotein translation
2. Blocks DNA damage repair
3. Decreases gene translation efficacy in glioblastoma
4. Induces glioblastoma death
5. Synergies with temozolomide and radiation

Green et al., Neuro-Oncology, 2015; Argueta et al., Oncotarget, 2018; Shang et al., Sci Rep, 2018; Wahba et al., MCT, 2018
**Selinexor**: First-in-Class, Oral Selective Inhibitor of Nuclear Export (SINE) Drug

Exportin 1 (XPO1) is the major nuclear export protein of:
1. Tumor suppressor proteins (TSPs, e.g. p53, pRb, IĸB, p27, p21, FOXOs)
2. eIF4E-bound proto-oncogene mRNAs (e.g. c-Myc, Bcl2, Bcl6, BclXL)

**Elevated XPO1 expression:**
1. Inactivates TSP’s by mislocalization
2. Enhances proto-oncoprotein translation

Selinexor is an oral selective inhibitor of XPO1 that:
1. Reactivates TSP’s and blocks proto-oncoprotein translation
2. Blocks DNA damage repair
3. Decreases gene translation efficacy in glioblastoma
4. Induces glioblastoma death
5. Synergies with temozolomide and radiation

Green et al., Neuro-Oncology, 2015; Argueta et al., Oncotarget, 2018; Shang et al., Sci Rep, 2018; Wahba et al., MCT, 2018

Presented By: Andrew B. Lassman, MS, MD
Overexpression of XPO1 Correlates with Poor Prognosis in Glioma

Liu X et al., J Hematol Oncol, 2016

Wu S et al., Front Oncol 2020

Presented By: Andrew B. Lassman, MS, MD
Selinexor Inhibits *In Vivo* Orthotopic GBM Patient-Derived-Tumors

Green et al., Neuro-Oncology, 2015
### KING (KPT-330 in Recurrent Glioblastoma) Study Design

**Primary Objectives:**
- ARM A: Surgical arm to explore intra-tumoral pharmacokinetics (PK)
- ARMs B-D: 6mPFS rate

**Patient Population:**
- Recurrent/Progressive GBM (after RT and Temozolomide), no prior bev/VEGFRi
- Age ≥18 years, KPS ≥60, measurable disease (arms B-D)

**Cycle = 4 w, treat until PD (RANO by local MD, MRI q 8 w)**

<table>
<thead>
<tr>
<th>Surgical Arm – PK Analysis</th>
<th>Medical Arms: Safety &amp; Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM A (n=8)</td>
<td>ARM B (n=24)</td>
</tr>
<tr>
<td>Selinexor: 50 mg/m² BIW</td>
<td>Selinexor: 50 mg/m² BIW</td>
</tr>
<tr>
<td>↓ Resection</td>
<td>Selinexor: 50 mg/m² BIW</td>
</tr>
<tr>
<td>↓ Resume Selinexor</td>
<td>Selinexor: 60 mg BIW</td>
</tr>
<tr>
<td></td>
<td>Selinexor: 80 mg QW</td>
</tr>
</tbody>
</table>

Presented By: Andrew B. Lassman, MS, MD
KING Study Results

Surgical Arm A – PK Analysis (WFNOS 2017 Results)

Pharmacokinetic results have demonstrated reasonable intra-tumor penetration with tumor concentration of SEL averaging 136 nM (~2h post dose, n=6) in a range of the mean in vitro IC$_{50}$ of ~130 nM.

Modified Intent to Treat (mITT) Population – Safety & Efficacy Analyses (ARMs B, C, D)

<table>
<thead>
<tr>
<th>ARM B</th>
<th>ARM C</th>
<th>ARM D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selinexor 50 mg/m$^2$ BIW 2 more arms added to explore dose/schedule</td>
<td>Selinexor 60 mg BIW Tolerable but efficacy limited</td>
<td>Selinexor 80 mg QW WFNOS 2017: Tolerable and responses observed (WFNOS 2017) → Expanded</td>
</tr>
</tbody>
</table>

Randomized to ARM C or D (1:1)

Presented By: Andrew B. Lassman, MS, MD
## Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>ARM A</th>
<th>ARM B</th>
<th>ARM C</th>
<th>ARM D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients Enrolled</td>
<td>8</td>
<td>24</td>
<td>14</td>
<td>30</td>
</tr>
<tr>
<td>Age: Years median (range)</td>
<td>58 (43-65)</td>
<td>50 (29-69)</td>
<td>52 (27-65)</td>
<td>56 (21-78)</td>
</tr>
<tr>
<td>Men (%) : Women (%)</td>
<td>88% : 12%</td>
<td>79% : 21%</td>
<td>64% : 36%</td>
<td>63% : 37%</td>
</tr>
<tr>
<td>Median Prior Therapies</td>
<td>2 (1-2)</td>
<td>1 (1-2)</td>
<td>1 (1-3)</td>
<td>2 (1-8)</td>
</tr>
<tr>
<td>Karnofsky Performance Score (KPS): Median</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients KPS – 60%</td>
<td>80%</td>
<td>90%</td>
<td>90%</td>
<td>80%</td>
</tr>
<tr>
<td>Patients KPS – 70% – 80%</td>
<td>5 (63%)</td>
<td>7 (29%)</td>
<td>4 (29%)</td>
<td>13 (43%)</td>
</tr>
<tr>
<td>Patients KPS – ≥90%</td>
<td>3 (37%)</td>
<td>15 (63%)</td>
<td>9 (64%)</td>
<td>16 (53%)</td>
</tr>
</tbody>
</table>

Presented By: Andrew B. Lassman, MS, MD
Treatment-Related non-Hematological Adverse Events in ≥10% of Patients (Safety)

<table>
<thead>
<tr>
<th>AE Term</th>
<th>Arm B – 50 mg/m² BIW (n=24)</th>
<th>Arm C – 60 mg BIW (n=14)</th>
<th>Arm D – 80 mg QW (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1/2</td>
<td>Grade 3</td>
<td>Grade 1/2</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>9 (37.5%)</td>
<td>1 (4.2%)</td>
<td>9 (64.3%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (29.2%)</td>
<td>--</td>
<td>5 (35.7%)</td>
</tr>
<tr>
<td>Decrease appetite</td>
<td>11 (45.8%)</td>
<td>--</td>
<td>10 (71.4%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (12.5%)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>9 (37.5%)</td>
<td>--</td>
<td>6 (42.9%)</td>
</tr>
<tr>
<td>Constipation</td>
<td>2 (8.3%)</td>
<td>--</td>
<td>4 (28.6%)</td>
</tr>
<tr>
<td>Constitutional</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>10 (41.7%)</td>
<td>7 (29.2%)</td>
<td>8 (57.1%)</td>
</tr>
<tr>
<td>Weight Loss</td>
<td>4 (16.7%)</td>
<td>--</td>
<td>5 (35.7%)</td>
</tr>
<tr>
<td>Malaise</td>
<td>--</td>
<td>--</td>
<td>3 (21.4%)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>9 (37.5%)</td>
<td>1 (4.2%)</td>
<td>2 (14.3%)</td>
</tr>
<tr>
<td>Vision Blurred</td>
<td>5 (20.8%)</td>
<td>1 (7.1%)</td>
<td>2 (14.3%)</td>
</tr>
</tbody>
</table>

- No Grade 4 treatment-related AEs were reported in ≥10% patients
- No Grade 5 treatment-related AEs were reported

Data cutoff 04-May-2020

Presented By: Andrew B. Lassman, MS, MD
## Treatment-Related Hematological Adverse Events in ≥10% of Patients (Safety)

<table>
<thead>
<tr>
<th>AE Term</th>
<th>Arm B – 50 mg/m² BIW (n=24)</th>
<th>Arm C – 60 mg BIW (n=14)</th>
<th>Arm D – 80 mg QW (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 1/2</td>
<td>Grade 3</td>
<td>Grade 1/2</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>5 (20.8%)</td>
<td>2 (8.3%)</td>
<td>--</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>3 (12.5%)</td>
<td>4 (16.7%)</td>
<td>--</td>
</tr>
<tr>
<td>Anemia</td>
<td>5 (20.8%)</td>
<td>--</td>
<td>1 (7.1%)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>14 (58.3%)</td>
<td>2 (8.3%)</td>
<td>4 (28.6%)</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>1 (4.2%)</td>
<td>1 (4.2%)</td>
<td>--</td>
</tr>
</tbody>
</table>

- No Grade 5 treatment-related hematological AEs were reported

Data cutoff: 04-May-2020
## KING Efficacy

<table>
<thead>
<tr>
<th></th>
<th>ARM B – 50 mg/m² BIW</th>
<th>ARM C – 60 mg BIW</th>
<th>ARM D – 80 mg QW</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td>24</td>
<td>14</td>
<td>30</td>
</tr>
<tr>
<td>6mPFS rate (95% CI)</td>
<td>10% (3 – 35)</td>
<td>7.69% (1 – 51)</td>
<td>17% (8 – 38)</td>
</tr>
<tr>
<td>6 cycle PFS rate (95% CI)</td>
<td>15% (5 – 40)</td>
<td>7.69% (1 – 51)</td>
<td>28% (15– 50)</td>
</tr>
<tr>
<td>Overall Response Rate (PR + CR)</td>
<td>8%</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td>Median OS (95% CI) months</td>
<td>10.5 (4.9 – 17.0)</td>
<td>8.5 (7.8 – NE)</td>
<td>10.2 (7.0-15.4)</td>
</tr>
</tbody>
</table>

Data cutoff 04-May-2020, response by local investigators per Response Assessment in Neuro-Oncology (RANO). CR=Complete Response, PR=Partial Response, OS=Overall Survival, PFS=Progression Free Survival

- 17% of patients on ARM D achieved 6-month PFS rate (180 days)
- 28% of patients on ARM D achieved 6 cycle PFS rate (180 – 14 days)
- Median OS for ARM D: 10.2 months.
Selinexor Tumor Effect

ARM B  
(50 mg/m² BIW)

ARM C  
(60 mg BIW)

ARM  
(80 mg QW)

Arms B-D pooled
↓ tumor size
29% of patients

Presented By: Andrew B. Lassman, MS, MD
Overall Survival

Median Overall Survival (95% CI)

- Arm B: 10.31 (4.93-16.95)
- Arm C: 8.48 (7.82-NA)
- Arm D: 10.15 (7.03-15.38)

Survival probability

No. at Risk

Arm B: 24 24 22 21 20 15 14 12 12 10 9 8 8 5 5 4 5 3 3 3 1 1 1 1 1 1 1 1 1 1
Arm C: 14 14 13 12 12 10 9 6 4 4 4 3 2 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0
Arm D: 30 26 26 23 22 22 21 16 13 12 11 10 9 8 6 5 5 5 3 3 3 3 3 2 2 1 1 1

Presented By: Andrew B. Lassman, MS, MD
ARM D – Survival

All Patients in Arm D (N=30)

Disease Assessment
- CR
- PR
- SD
- PD

Last Dose
- New Anti-GBM TrT
- OS Censored

Time scale changes to 6 month units

Presented By: Andrew B. Lassman, MS, MD
Patient 1: Durable PR 3L Therapy in Recurrent GBM

64 yo man uMGMT IDH* (IHC & PCR)

RT + TMZ

Selinexor

Durable PR

PD #2 (post-op)

TMZ x 5

AKTi+mTORi

PD #1

- Durable PR (↓72%)
- 80 mg QW
- > 3y
Patient 2: Complete Response Patient Profile

36 year old man, RT+TMZ+/Deptux-m x 7 m

\[ IDH^{wt} \] (IHC & PCR), m\textit{MGMT}

Selinexor

80 mg/w

CR, on treatment > 1y
Molecular Predictors of Response to Selinexor in Recurrent Glioblastoma (GBM)

Mutations Associated with Improved Survival in Selinexor-Treated Patients

- Patients with adequate selinexor exposure (>21 days and > 3 doses) were exome and RNA sequenced.
- Three genes showed significant correlation between mutation and improved survival with selinexor treatment.
- Notably, the PDX1 transcription factor protein contains an XPO1 nuclear export sequence and the observed mutations have been shown to impact PDX1 mediated transcription of its target genes.

For more details please see Abstract #: BIOM-26
Abstract Title: Molecular predictors of response to selinexor in recurrent glioblastoma (GBM)
KING Conclusions

- Selinexor achieves adequate intra-tumor penetration
- 80 mg po QW is recommended dose for further evaluation
- Side effects expected and manageable
- Anti-tumor activity observed, supporting further development
- Molecular correlative analyses ongoing to identify enrichment biomarker(s)
  - Abstract #: BIOM-26: Molecular predictors of response to selinexor in recurrent GBM
- Ongoing phase I/II trial in newly diagnosed GBM (NCT04421378), enrolling
  - Abstract #: RTID-08: A Phase 1/2 study of Selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma

Presented By: Andrew B. Lassman, MS, MD
Acknowledgments

Patients, their families, and caregivers

Investigators, co-investigators and study teams at each participating center:

- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY
- Dana Farber Cancer Institute, Boston, MA
- Erasmus MC Cancer Center, Rotterdam, The Netherlands
- Massachusetts General Hospital, Boston, MA
- University of Groningen, Groningen, The Netherlands
- Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Presented By: Andrew B. Lassman, MS, MD